Contract Manufacturers Cautioned On Allure of Novel Cell and Gene Therapies
Meanwhile, Monoclonal Antibodies Remain Where It’s At In Recombinant Biopharmaceutical Manufacturing
Executive Summary
Contract development and manufacturing organizations are fielding requests from sponsors to ramp up for emerging novel treatment modalities like CAR-T cells and gene therapies but shouldn't "over-invest," consultant advises. Meanwhile, MAb production capacity, already huge, is growing 50% over the next five years to meet surging demand.